Antibiotic Resistance Market Size, Share, Growth, Analysis, 2034

cUTI (Complicated Urinary Tract Infections)
CDI (Clostridioides difficile Infection)
ABSSSI (Acute bacterial skin and skin structure infections)
HABP (Hospital-acquired bacterial pneumonia)
CABP (Community-acquired pneumonia)
cIAI (Complicated intra-abdominal infection)
BSI (Bloodstream infection)

coli
pneumoniae
aeruginosa
aureus
baumannii
influenzae
difficile
faecium

Oxazolidinones
Lipoglycopeptides
Tetracyclines
Combination therapies
Cephalosporins
Others

Protein Synthesis Inhibitors
Cell Wall Synthesis Inhibitors
RNA Synthesis Inhibitors
DNA Synthesis Inhibitors
Others

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

North America
1. North America Antibiotic Resistance Market By Disease 2022-2034 (USD MILLION/ Units)
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
2. North America Antibiotic Resistance Market By Pathogen 2022-2034 (USD MILLION/ Units)
  1. coli
  2. pneumoniae
  3. aeruginosa
  4. aureus
  5. baumannii
  6. influenzae
  7. difficile
  8. faecium
3. North America Antibiotic Resistance Market By Drug Class 2022-2034 (USD MILLION/ Units)
  1. Oxazolidinones
  2. Lipoglycopeptides
  3. Tetracyclines
  4. Combination therapies
  5. Cephalosporins
  6. Others
4. North America Antibiotic Resistance Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
  1. Protein Synthesis Inhibitors
  2. Cell Wall Synthesis Inhibitors
  3. RNA Synthesis Inhibitors
  4. DNA Synthesis Inhibitors
  5. Others
5. North America Antibiotic Resistance Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
6. U.S.
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
7. Canada
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
Europe
1. Europe Antibiotic Resistance Market By Disease 2022-2034 (USD MILLION/ Units)
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
2. Europe Antibiotic Resistance Market By Pathogen 2022-2034 (USD MILLION/ Units)
  1. coli
  2. pneumoniae
  3. aeruginosa
  4. aureus
  5. baumannii
  6. influenzae
  7. difficile
  8. faecium
3. Europe Antibiotic Resistance Market By Drug Class 2022-2034 (USD MILLION/ Units)
  1. Oxazolidinones
  2. Lipoglycopeptides
  3. Tetracyclines
  4. Combination therapies
  5. Cephalosporins
  6. Others
4. Europe Antibiotic Resistance Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
  1. Protein Synthesis Inhibitors
  2. Cell Wall Synthesis Inhibitors
  3. RNA Synthesis Inhibitors
  4. DNA Synthesis Inhibitors
  5. Others
5. Europe Antibiotic Resistance Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
6. U.K.
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
7. Germany
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
8. France
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
9. Spain
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
10. Italy
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
11. Russia
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
12. Nordic
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
13. Benelux
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
14. Rest of Europe
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
APAC
1. APAC Antibiotic Resistance Market By Disease 2022-2034 (USD MILLION/ Units)
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
2. APAC Antibiotic Resistance Market By Pathogen 2022-2034 (USD MILLION/ Units)
  1. coli
  2. pneumoniae
  3. aeruginosa
  4. aureus
  5. baumannii
  6. influenzae
  7. difficile
  8. faecium
3. APAC Antibiotic Resistance Market By Drug Class 2022-2034 (USD MILLION/ Units)
  1. Oxazolidinones
  2. Lipoglycopeptides
  3. Tetracyclines
  4. Combination therapies
  5. Cephalosporins
  6. Others
4. APAC Antibiotic Resistance Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
  1. Protein Synthesis Inhibitors
  2. Cell Wall Synthesis Inhibitors
  3. RNA Synthesis Inhibitors
  4. DNA Synthesis Inhibitors
  5. Others
5. APAC Antibiotic Resistance Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
6. China
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
7. Korea
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
8. Japan
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
9. India
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
10. Australia
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
11. Taiwan
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
12. South East Asia
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
13. Rest of Asia-Pacific
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
Middle East and Africa
1. Middle East and Africa Antibiotic Resistance Market By Disease 2022-2034 (USD MILLION/ Units)
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
2. Middle East and Africa Antibiotic Resistance Market By Pathogen 2022-2034 (USD MILLION/ Units)
  1. coli
  2. pneumoniae
  3. aeruginosa
  4. aureus
  5. baumannii
  6. influenzae
  7. difficile
  8. faecium
3. Middle East and Africa Antibiotic Resistance Market By Drug Class 2022-2034 (USD MILLION/ Units)
  1. Oxazolidinones
  2. Lipoglycopeptides
  3. Tetracyclines
  4. Combination therapies
  5. Cephalosporins
  6. Others
4. Middle East and Africa Antibiotic Resistance Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
  1. Protein Synthesis Inhibitors
  2. Cell Wall Synthesis Inhibitors
  3. RNA Synthesis Inhibitors
  4. DNA Synthesis Inhibitors
  5. Others
5. Middle East and Africa Antibiotic Resistance Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
6. UAE
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
7. Turkey
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
8. Saudi Arabia
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
9. South Africa
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
10. Egypt
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
11. Nigeria
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
12. Rest of MEA
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
LATAM
1. LATAM Antibiotic Resistance Market By Disease 2022-2034 (USD MILLION/ Units)
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
2. LATAM Antibiotic Resistance Market By Pathogen 2022-2034 (USD MILLION/ Units)
  1. coli
  2. pneumoniae
  3. aeruginosa
  4. aureus
  5. baumannii
  6. influenzae
  7. difficile
  8. faecium
3. LATAM Antibiotic Resistance Market By Drug Class 2022-2034 (USD MILLION/ Units)
  1. Oxazolidinones
  2. Lipoglycopeptides
  3. Tetracyclines
  4. Combination therapies
  5. Cephalosporins
  6. Others
4. LATAM Antibiotic Resistance Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
  1. Protein Synthesis Inhibitors
  2. Cell Wall Synthesis Inhibitors
  3. RNA Synthesis Inhibitors
  4. DNA Synthesis Inhibitors
  5. Others
5. LATAM Antibiotic Resistance Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
6. Brazil
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
7. Mexico
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
8. Argentina
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
9. Chile
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
10. Colombia
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies
11. Rest of LATAM
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
  8. coli
  9. pneumoniae
  10. aeruginosa
  11. aureus
  12. baumannii
  13. influenzae
  14. difficile
  15. faecium
  16. Oxazolidinones
  17. Lipoglycopeptides
  18. Tetracyclines
  19. Combination therapies
  20. Cephalosporins
  21. Others
  22. Protein Synthesis Inhibitors
  23. Cell Wall Synthesis Inhibitors
  24. RNA Synthesis Inhibitors
  25. DNA Synthesis Inhibitors
  26. Others
  27. Hospital Pharmacies
  28. Retail Pharmacies
  29. Online Pharmacies

Market Segmentation